BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma
The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.
Best Practices for the Medical Oncology Boards
A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.
Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma
Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors
Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.
Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC
The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.
